CAR T therapies hold the potential for durable, life-changing solutions for patients who have few or no therapeutic options, but only if health authorities and payers agree to reimbursement. Novartis managed to bridge the gap between evidence of efficacy and value in this space with a vari...
if you look at the inpatient reimbursement procedures in place, we often see diagnosis-related groups using bundled payments, where payment encompasses all treatment at a flat rate, in which case the pressure is on the provider to push down on the cost of therapy.” ...
Reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs expenses while interviewing with Juno that we pay or reimburse, your ...
The pace of development in the CAR-T world, both scientific and commercial, is showing no sign of letting up. We have selected some highlights since ourlast review in Maybelow. Beginning the month with the annual meeting of the American Society of Clinical Oncology (ASCO) in...
Curocell, a Korean biotechnology company specializing in CAR-T (chimeric antigen receptor t) therapies, has officially submitted an application to the Health Insurance Review and Assessment Service (HIRA) for the reimbursement listing of its CAR-T treatm
January 2023 was another highlight for the company when UK’s National Institute for Health and Care Excellence (NICE) moved Yescarta from availability under Cancer Drugs Fund to reimbursement under the National Health Service (NHS). In June 2023, the company changed its market authorization from ...
Despite the strong efficacy data in clinical trials, there are three key challenges affecting the commercialization of CAR Ts: complex manufacturing and supply chain, high-touch commercial model, and reimbursement challenges (Exhibit 2). Complex manufacturing and su...
HTA88 Reimbursement of CAR-T Cell Therapies in Europe: Key Challenges from Precedents and Lessons for Futuredoi:10.1016/j.jval.2023.09.1772M. KowalskaA. KocwinJ. ZyrekE. HannaC. RémuzatC. FrancoisValue in Health
China grapples with providing access to CAR T therapies The process of manufacturing autologous T-cell therapies is technically challenging when compared with other oncology drugs, making the overall cost of developing CAR T therapies significantly higher. A challenging reimbursement environment for drugs...
目前,美国FDA已经正式批准了四款CAR-T细胞治疗产品,并且在未来还将有望迎来更多CAR-T细胞上市。 但是,除了CAR-T细胞治疗所具有的毒副作用之外,价格是限制患者受益的一大关键。在欧美国家,药物产品的定价是基于其价值,诺华CEO曾表示,CAR-T细胞疗法的价格基于四项价值衡量标准:在临床和生活质量方面为患者带来的改善,...